Markers in Cardiology
A Case-Oriented Approach
1st Edition
Will be published approx. on 30. July 2007
Book
Hardback
272 pages
978-1-4051-3418-7 (ISBN)
Description
With the rapid development of the field of cardiac biomarkers comes a need for updated guidance on how to use them clinically. Drs. Adams, Jaffe, and Apple meet that need with this timely reference.
Taking a case-oriented approach for the greatest clinical relevance, the book bridges the gap between science and practice. If you use - or want to use - cardiac markers such as BNP and troponin to help your patients, you will find this clear and comprehensive reference provides a dependable source of valuable information.
The 19 chapters are divided into three parts:
* Cardiac Troponins
* Natriuretic Peptides
* Contemporary Markers of Risk
The authors cover the technical, clinical, and outcome assessments for each marker used in clinical practice. After each case scenario, an extensive discussion explains the clinical decisions and provides valuable context.
Taking a case-oriented approach for the greatest clinical relevance, the book bridges the gap between science and practice. If you use - or want to use - cardiac markers such as BNP and troponin to help your patients, you will find this clear and comprehensive reference provides a dependable source of valuable information.
The 19 chapters are divided into three parts:
* Cardiac Troponins
* Natriuretic Peptides
* Contemporary Markers of Risk
The authors cover the technical, clinical, and outcome assessments for each marker used in clinical practice. After each case scenario, an extensive discussion explains the clinical decisions and provides valuable context.
Reviews / Votes
"I think this is a good book and good value for money. It is fairly light reading and I found myself wanting to make notes and use it as a point of reference as it pulls things together well. Therefore, I would recommend it to others." (Cardiology News, February 2009)More details
Language
English
Place of publication
Hoboken
United Kingdom
Publishing group
John Wiley and Sons Ltd
Target group
Professional and scholarly
Product notice
Pop-up book
sewn/stitched
Cloth over boards
Dimensions
Height: 230 mm
Width: 164 mm
Thickness: 20 mm
Weight
612 gr
ISBN-13
978-1-4051-3418-7 (9781405134187)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
E-Book
05/2008
Wiley-Blackwell
€106.99
Available for download
Persons
Jesse E. Adams, MD FACC
University of Louisville
Division of Cardiology
100 Mallard Creek
Louisville, KY 40202
USA
Fred Apple, PhD
Department of Laboratory Medicine and Pathology
Hennepin County Medical Center and University of Minnesota School of Medicine
Minneapolis, MN
USA
Allan S. Jaffe, MD
Cardiovascular Division and Cardiovascular Research Institute and Division of Laboratory Medicine
Mayo Clinic and Medical School
Rochester, Minnesota
USA
University of Louisville
Division of Cardiology
100 Mallard Creek
Louisville, KY 40202
USA
Fred Apple, PhD
Department of Laboratory Medicine and Pathology
Hennepin County Medical Center and University of Minnesota School of Medicine
Minneapolis, MN
USA
Allan S. Jaffe, MD
Cardiovascular Division and Cardiovascular Research Institute and Division of Laboratory Medicine
Mayo Clinic and Medical School
Rochester, Minnesota
USA
Content
Contents. Contributors.
Preface.
Part 1 Cardiac troponins.
1 Basics of cardiac troponin: practical aspects of assays, potential.
analytical confounders, and clinical interpretation.
Fred S. Apple (University of Minnesota School of Medicine).
2 Diagnostic use of cardiac troponins in ST-segment elevation.
myocardial infarction.
Susanne Korff (Medizinische Universitaetsklinik Heidelberg), Hugo A. Katus (Department of Cardiology), Evangelos Giannitsis (Department of Cardiology).
3 Therapeutic implications of cardiac troponins in ST-segment.
elevation and non-ST-segment elevation myocardial.
infarction.
Tracy Y. Wang, John M. Castor, L. Kristin Newby.
4 Ischemic heart disease in the absence of overt coronary.
artery disease.
Allan S. Jaffe (Mayo Clinic).
5 So you think you have a "false positive'' troponin?.
Jesse E. Adams (Jewish Hospital Heart and Lung Institute).
6 Use of cardiac troponin in patients in non-ischemic pathologies.
and exposure to environmental toxins.
Fred S. Apple (University of Minnesota School of Medicine).
7 Cardiac troponins in patients with congestive heart failure.
Jesse Adams (Jewish Hospital Heart and Lung Institute).
8 Troponins and the critically Ill patient.
Jose Antonio Perez (Mayo Clinic & Medical School), Luciano Babuin (Cardiovascular Division & Cardiovascular), Allan S. Jaffe (Mayo Clinic).
9 Cardiac troponins and renal failure.
Suresh Pothuru (University of Maryland), Christopher deFilippi (University of Maryland).
10 Cardiac biomarkers: detection of in-hospital myocardial.
reinfarction.
Fred S. Apple (University of Minnesota School of Medicine).
Part 2 Natriuretic peptides.
11 The future: interpreting new guidelines for myocardial.
infarction.
Allan S. Jaffe (Mayo Clinic).
12 Basics of natriuretic peptides: practical aspects of assays,.
potential analytical confounders, and clinical interpretation.
Alan H.B. Wu (San Francisco General Hospital).
13 Natriruetic peptides in clinical practice.
Alan Maisel (University of California).
14 Outpatient evaluation for cardiovascular diseases using.
natriuretic peptide testing.
Aaron L. Baggish (Massachusetts General Hospital), James L. Januzzi (Harvard Medical School).
15 Natriuretic peptides in patients with renal failure.
Peter A. McCullough (William Beaumont Hospital).
16 Congestive heart failure: treatment implications of natriuretic.
peptides.
W Frank Peacock (Emergency Cardiology Research).
17 Utilizing multimarker strategies in patients who present with.
congestive heart failure.
Johannes Mair (Universitaetsklinik fuer Innere Medizin).
Part 3 Contemporary markers of risk.
18 Clinical integration of C-reactive protein for primary and.
secondary risk factor stratification.
Jesse E. Adams (Jewish Hospital Heart and Lung Institute).
19 Lipoprotein subfraction analysis using nuclear magnetic.
resonance spectroscopy.
William C. Cromwell (Presbyterian Center for Preventive Cardiology), Harold E. Bays (L-Marc Research Center), Peter P. Toth (Director of Preventive Cardiology).
Index
Preface.
Part 1 Cardiac troponins.
1 Basics of cardiac troponin: practical aspects of assays, potential.
analytical confounders, and clinical interpretation.
Fred S. Apple (University of Minnesota School of Medicine).
2 Diagnostic use of cardiac troponins in ST-segment elevation.
myocardial infarction.
Susanne Korff (Medizinische Universitaetsklinik Heidelberg), Hugo A. Katus (Department of Cardiology), Evangelos Giannitsis (Department of Cardiology).
3 Therapeutic implications of cardiac troponins in ST-segment.
elevation and non-ST-segment elevation myocardial.
infarction.
Tracy Y. Wang, John M. Castor, L. Kristin Newby.
4 Ischemic heart disease in the absence of overt coronary.
artery disease.
Allan S. Jaffe (Mayo Clinic).
5 So you think you have a "false positive'' troponin?.
Jesse E. Adams (Jewish Hospital Heart and Lung Institute).
6 Use of cardiac troponin in patients in non-ischemic pathologies.
and exposure to environmental toxins.
Fred S. Apple (University of Minnesota School of Medicine).
7 Cardiac troponins in patients with congestive heart failure.
Jesse Adams (Jewish Hospital Heart and Lung Institute).
8 Troponins and the critically Ill patient.
Jose Antonio Perez (Mayo Clinic & Medical School), Luciano Babuin (Cardiovascular Division & Cardiovascular), Allan S. Jaffe (Mayo Clinic).
9 Cardiac troponins and renal failure.
Suresh Pothuru (University of Maryland), Christopher deFilippi (University of Maryland).
10 Cardiac biomarkers: detection of in-hospital myocardial.
reinfarction.
Fred S. Apple (University of Minnesota School of Medicine).
Part 2 Natriuretic peptides.
11 The future: interpreting new guidelines for myocardial.
infarction.
Allan S. Jaffe (Mayo Clinic).
12 Basics of natriuretic peptides: practical aspects of assays,.
potential analytical confounders, and clinical interpretation.
Alan H.B. Wu (San Francisco General Hospital).
13 Natriruetic peptides in clinical practice.
Alan Maisel (University of California).
14 Outpatient evaluation for cardiovascular diseases using.
natriuretic peptide testing.
Aaron L. Baggish (Massachusetts General Hospital), James L. Januzzi (Harvard Medical School).
15 Natriuretic peptides in patients with renal failure.
Peter A. McCullough (William Beaumont Hospital).
16 Congestive heart failure: treatment implications of natriuretic.
peptides.
W Frank Peacock (Emergency Cardiology Research).
17 Utilizing multimarker strategies in patients who present with.
congestive heart failure.
Johannes Mair (Universitaetsklinik fuer Innere Medizin).
Part 3 Contemporary markers of risk.
18 Clinical integration of C-reactive protein for primary and.
secondary risk factor stratification.
Jesse E. Adams (Jewish Hospital Heart and Lung Institute).
19 Lipoprotein subfraction analysis using nuclear magnetic.
resonance spectroscopy.
William C. Cromwell (Presbyterian Center for Preventive Cardiology), Harold E. Bays (L-Marc Research Center), Peter P. Toth (Director of Preventive Cardiology).
Index